Last checked at 8 Jun 2021 14:32
Grant of options
London, UK - 08 June 2021: Oxford Biomedica plc ("Oxford Biomedica" or the "Company") (LSE:OXB), a leading gene and cell therapy group announces that on 08 June 2021 nil-cost share options over ordinary shares of 50 pence each in the Company were granted under the Oxford Biomedica 2015 Deferred Bonus Plan ("DBP") and the Oxford Biomedica 2015 Long Term Incentive Plan ("LTIP").
2021 LTIP Awards
Name of individual | Title | Number of shares subject to the 2021 DBP award | Number of shares subject to the 2021 LTIP award | Total shares over which options now held | Percentage of current issued share capital under option |
John Dawson | Chief Executive Officer | 20,221 | 80,460 | 848,393 | 1.0% |
Stuart Paynter | Chief Financial Officer | 11,642 | 47,966 | 247,902 | 0.3% |
James Miskin | Chief Technical Officer | 4,897 | 18,943 | 154,914 | 0.2% |
Kyriacos Mitrophanous | Chief Scientific Officer | 4,944 | 19,125 | 171,545 | 0.2% |
Nick Page | Chief Operations Officer | 5,170 | 19,999 | 89,436 | 0.1% |
Helen Stephenson-Ellis | Chief People Officer | 3,331 | 13,131 | 75,758 | 0.09% |
Jason Slingsby | Chief Business Officer | 4,595 | 18,114 | 108,867 | 0.1% |
Natalie Walter | General Counsel | 4,143 | 16,028 | 66,905 | 0.08% |
Under the terms of the DBP, the DBP awards will become exercisable as to one third of the shares subject to each award on each of the first three anniversaries of the grant date.
The LTIP awards are subject to performance conditions. As set out in the 2020 Directors' Remuneration Report, the performance condition is based on TSR (40% of the award, assessed over the three years from grant); revenue growth (40% of the award, assessed over financial years 2021, 2022 and 2023) and strategic milestones (20% of the award). Details of the measures are included in the 2020 Directors' Remuneration Report, other than as regards the strategic milestones, which are commercially sensitive and will be disclosed in due course.
The LTIP awards granted to John Dawson and Stuart Paynter will "vest" following the assessment of the performance condition, but will only be "released" so that they can be exercised following the end of a further two year holding period. The2021 awards granted to other participants will vest and be released following the assessment of the performance condition.
The above table reflects the grant of an award (1,320) to rectify an administrative error in the 2020 LTIP award granted to the General Counsel and the lapse of an award (7,875) to rectify an administrative error in the 2020 LTIP award granted to the Chief Financial Officer ("CFO") on 26 June 2020. These amendments were also reflected in the Company's 2020 Report & Accounts.
RSU awards
In addition, on 08 June 2021 a nil-cost share option over 4,406 shares of 50 pence each in the Company was also granted under the LTIP scheme to Alexander Lewis, Chief of Staff. The RSU award is not subject to performance conditions and will become exercisable from the third anniversary of the grant date. The total shares over which options are held by Alexander Lewis is 69,227, representing 0.08% of the current issued share capital under option.
The current issued share capital of the Company is 82,555,443 ordinary shares of 50 pence each.
Notification of Dealing Form
1. | Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") | |||||||||
a) | Name | John Dawson | ||||||||
2. | Reason for the notification | |||||||||
a) | Position/status | Chief Executive Officer
| ||||||||
b) | Initial notification/ amendment | Initial Notification | ||||||||
3. | Details of the Issuer | |||||||||
a) | Name | Oxford Biomedica plc | ||||||||
b) | LEI code | 213800S1GVQNXQ15K851 | ||||||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||||
a) | Description of the financial instrument
Identification code | Ordinary Shares of 50 pence each
ISIN: GB00BDFBVT43 | ||||||||
b) | Nature of the transaction | Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan and Deferred Bonus Plan. No consideration was paid for the grant of awards. | ||||||||
c) | Price(s) and volumes(s) | 2021 LTIP Award
2021 DBP Award
| ||||||||
d) | Aggregated information - Aggregate volume
- Price
|
Awards granted over 100,681 shares in total
N/A
| ||||||||
e) | Date of the transaction | 2021-06-08 | ||||||||
f) | Place of the transaction | Outside of trading venue | ||||||||
1. | Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") | |||||||||
a) | Name | Stuart Paynter | ||||||||
2. | Reason for the notification | |||||||||
a) | Position/status | Chief Financial Officer
| ||||||||
b) | Initial notification/ amendment | Initial Notification | ||||||||
3. | Details of the Issuer | |||||||||
a) | Name | Oxford Biomedica plc | ||||||||
b) | LEI code | 213800S1GVQNXQ15K851 | ||||||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||||
a) | Description of the financial instrument
Identification code | Ordinary Shares of 50 pence each
ISIN: GB00BDFBVT43 | ||||||||
b) | Nature of the transaction | Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan and Deferred Bonus Plan. No consideration was paid for the grant of awards. | ||||||||
c) | Price(s) and volumes(s) | 2021 LTIP Award
2021 DBP Award
| ||||||||
d) | Aggregated information - Aggregate volume
- Price
|
Awards granted over 59,608 shares in total
N/A
| ||||||||
e) | Date of the transaction | 2021-06-08 | ||||||||
f) | Place of the transaction | Outside of trading venue | ||||||||
1. | Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") | |||||||||
a) | Name | James Miskin | ||||||||
2. | Reason for the notification | |||||||||
a) | Position/status | Chief Technical Officer | ||||||||
b) | Initial notification/ amendment | Initial Notification | ||||||||
3. | Details of the Issuer | |||||||||
a) | Name | Oxford Biomedica plc | ||||||||
b) | LEI code | 213800S1GVQNXQ15K851 | ||||||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||||
a) | Description of the financial instrument
Identification code | Ordinary Shares of 50 pence each
ISIN: GB00BDFBVT43 | ||||||||
b) | Nature of the transaction | Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan and Deferred Bonus Plan. No consideration was paid for the grant of awards. | ||||||||
c) | Price(s) and volumes(s) | 2021 LTIP Award
2021 DBP Award
| ||||||||
d) | Aggregated information - Aggregate volume
- Price
|
Awards granted over 23,840 shares in total
N/A
| ||||||||
e) | Date of the transaction | 2021-06-08 | ||||||||
f) | Place of the transaction | Outside of trading venue | ||||||||
1. | Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") | |||||||||
a) | Name | Kyriacos Mitrophanous | ||||||||
2. | Reason for the notification | |||||||||
a) | Position/status | Chief Scientific Officer | ||||||||
b) | Initial notification/ amendment | Initial Notification | ||||||||
3. | Details of the Issuer | |||||||||
a) | Name | Oxford Biomedica plc | ||||||||
b) | LEI code | 213800S1GVQNXQ15K851 | ||||||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||||
a) | Description of the financial instrument
Identification code | Ordinary Shares of 50 pence each
ISIN: GB00BDFBVT43 | ||||||||
b) | Nature of the transaction | Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan and Deferred Bonus Plan. No consideration was paid for the grant of awards. | ||||||||
c) | Price(s) and volumes(s) | 2021 LTIP Award
2021 DBP Award
| ||||||||
d) | Aggregated information - Aggregate volume
- Price
|
Awards granted over 24,069 shares in total
N/A
| ||||||||
e) | Date of the transaction | 2021-06-08 | ||||||||
f) | Place of the transaction | Outside of trading venue | ||||||||
1. | Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") | |||||||||
a) | Name | Nick Page | ||||||||
2. | Reason for the notification | |||||||||
a) | Position/status | Chief Operations Officer | ||||||||
b) | Initial notification/ amendment | Initial Notification | ||||||||
3. | Details of the Issuer | |||||||||
a) | Name | Oxford Biomedica plc | ||||||||
b) | LEI code | 213800S1GVQNXQ15K851 | ||||||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||||
a) | Description of the financial instrument
Identification code | Ordinary Shares of 50 pence each
ISIN: GB00BDFBVT43 | ||||||||
b) | Nature of the transaction | Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan and Deferred Bonus Plan. No consideration was paid for the grant of awards. | ||||||||
c) | Price(s) and volumes(s) | 2021 LTIP Award
2021 DBP Award
| ||||||||
d) | Aggregated information - Aggregate volume
- Price
|
Awards granted over 25,169 shares in total
N/A
| ||||||||
e) | Date of the transaction | 2021-06-08 | ||||||||
f) | Place of the transaction | Outside of trading venue | ||||||||
1. | Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") | |||||||||
a) | Name | Helen Stephenson-Ellis | ||||||||
2. | Reason for the notification | |||||||||
a) | Position/status | Chief People Officer | ||||||||
b) | Initial notification/ amendment | Initial Notification | ||||||||
3. | Details of the Issuer | |||||||||
a) | Name | Oxford Biomedica plc | ||||||||
b) | LEI code | 213800S1GVQNXQ15K851 | ||||||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||||
a) | Description of the financial instrument
Identification code | Ordinary Shares of 50 pence each
ISIN: GB00BDFBVT43 | ||||||||
b) | Nature of the transaction | Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan and Deferred Bonus Plan. No consideration was paid for the grant of awards. | ||||||||
c) | Price(s) and volumes(s) | 2020 LTIP Award
2021 DBP Award
| ||||||||
d) | Aggregated information - Aggregate volume
- Price
|
Awards granted over 16,462 shares in total
N/A
| ||||||||
e) | Date of the transaction | 2021-06-08 | ||||||||
f) | Place of the transaction | Outside of trading venue | ||||||||
1. | Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") | |||||||||
a) | Name | Jason Slingsby | ||||||||
2. | Reason for the notification | |||||||||
a) | Position/status | Chief Business Officer | ||||||||
b) | Initial notification/ amendment | Initial Notification | ||||||||
3. | Details of the Issuer | |||||||||
a) | Name | Oxford Biomedica plc | ||||||||
b) | LEI code | 213800S1GVQNXQ15K851 | ||||||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||||
a) | Description of the financial instrument
Identification code | Ordinary Shares of 50 pence each
ISIN: GB00BDFBVT43 | ||||||||
b) | Nature of the transaction | Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan and Deferred Bonus Plan. No consideration was paid for the grant of awards. | ||||||||
c) | Price(s) and volumes(s) | 2021 LTIP Award
2021 DBP Award
| ||||||||
d) | Aggregated information - Aggregate volume
- Price
|
Awards granted over 22,709 shares in total
N/A
| ||||||||
e) | Date of the transaction | 2021-06-08 | ||||||||
f) | Place of the transaction | Outside of trading venue | ||||||||
1. | Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") | |||||||||
a) | Name | Natalie Walter | ||||||||
2. | Reason for the notification | |||||||||
a) | Position/status | General Counsel | ||||||||
b) | Initial notification/ amendment | Initial Notification | ||||||||
3. | Details of the Issuer | |||||||||
a) | Name | Oxford Biomedica plc | ||||||||
b) | LEI code | 213800S1GVQNXQ15K851 | ||||||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||||
a) | Description of the financial instrument
Identification code | Ordinary Shares of 50 pence each
ISIN: GB00BDFBVT43 | ||||||||
b) | Nature of the transaction | Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan and Deferred Bonus Plan. No consideration was paid for the grant of awards. | ||||||||
c) | Price(s) and volumes(s) | 2020 LTIP Award
2021 DBP Award
| ||||||||
d) | Aggregated information - Aggregate volume
- Price
|
Awards granted over 20,171 shares in total
N/A
| ||||||||
e) | Date of the transaction | 2021-06-08 | ||||||||
f) | Place of the transaction | Outside of trading venue | ||||||||
1. | Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") | |||||
a) | Name | Alexander Lewis | ||||
2. | Reason for the notification | |||||
a) | Position/status | Chief of Staff | ||||
b) | Initial notification/ amendment | Initial Notification | ||||
3. | Details of the Issuer | |||||
a) | Name | Oxford Biomedica plc | ||||
b) | LEI code | 213800S1GVQNXQ15K851 | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument
Identification code | Ordinary Shares of 50 pence each
ISIN: GB00BDFBVT43 | ||||
b) | Nature of the transaction | Grant of award over Ordinary Shares under the Company's Executive Share Option Scheme. No consideration was paid for the grant of awards. | ||||
c) | Price(s) and volumes(s) | 2021 RSU Award
| ||||
d) | Aggregated information - Aggregate volume
- Price
|
4,406
N/A
| ||||
e) | Date of the transaction | 2021-06-08 | ||||
f) | Place of the transaction | Outside of trading venue | ||||
-Ends-
For further information, please contact: |
|
Oxford Biomedica plc: Natalie Walter, Company Secretary |
Tel: +44 (0)1865 783 000 |
About Oxford Biomedica
Oxford Biomedica (LSE:OXB) is a leading, fully integrated, gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford Biomedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology, CNS disorders, liver diseases and respiratory disease. The Group has also entered into a number of partnerships, including with Novartis, Bristol Myers Squibb, Sio Gene Therapies, Orchard Therapeutics, Santen, Beam Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations, through which it has long-term economic interests in other potential gene and cell therapy products. Additionally the group has signed a three year master supply and development agreement with AstraZeneca for large-scale manufacturing of the adenoviral based COVID-19 vaccine candidate, AZD1222. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 670 people. Further information is available at www.oxb.com